Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Teva Pharmaceutical Industries has seen its fair value estimate move from about US$35.32 to about US$36.77, with analysts tightening their valuation ranges as they weigh upcoming pipeline events into 2026. While the discount rate assumption is essentially unchanged at about 8.52%, the revenue growth outlook now sits closer to about 1.05%. This reflects mixed views on how quickly Teva can translate its pipeline and core business into higher sales. As you read on, keep an eye on how this evolving narrative shapes future updates so you can stay tuned to the shifts that matter most for the stock story.
Jefferies lifted its Teva price target to US$40 from US$29 and called the stock a top 2026 idea, linking the higher valuation to expectations that the research and development engine could start to bear fruit and support a more favorable long term terminal value.
Truist raised its Teva price target to US$36 from US$32 and highlighted an “affordable medicines” theme heading into 2026, which the firm views as supportive for the company as it looks to turn its pipeline and core business into steadier growth.
Across the recent notes from Jefferies, Truist, Scotiabank, and Barclays, the common thread is a willingness to reward Teva for potential execution on its pipeline, as well as the possibility of better research productivity and more consistent growth, even as analysts continue to monitor how much of this is already reflected in current valuation ranges.
🐻 Bearish Takeaways
Jefferies explicitly pointed out that a key hurdle is convincing investors to ascribe a positive terminal value to Teva’s research and development efforts, highlighting lingering skepticism around the company’s ability to turn its pipeline into sustained value.
Across the January research updates, analysts are focused on several pipeline catalysts and growth themes but also flag reservations around how quickly those efforts might translate into earnings and how much upside is already priced into higher targets such as the US$40 level set by Jefferies.
Teva issued 2026 revenue guidance in a range of about US$16.4 million to about US$16.8 million, giving you a clearer sense of management’s medium term expectations for the top line.
The company laid out guidance through 2030, with 2026 revenues expected to be flat to slightly down versus 2025 while operating profit is guided to grow, followed by low single digit revenue growth in 2027 with a 30% increase in operating profit over 2026, and a mid single digit revenue CAGR from 2026 to 2030 with operating profit rising by more than 30% over 2026.
Teva submitted a New Drug Application to the U.S. FDA for an olanzapine extended release injectable suspension for once monthly treatment of schizophrenia in adults, aiming to support real world adherence and stability for a broad group of patients.
The company launched Teva Rise, an open innovation platform that plans to partner with startups and technology firms in areas such as AI, smart manufacturing, digital health and biotech, with intended investment of tens of millions of US dollars over the coming years, at the same time Reuters highlighted that drugmakers, including Teva, are using AI to support clinical trials and regulatory submissions.
The Fair Value Estimate has risen slightly from about US$35.32 to about US$36.77.
The Discount Rate is essentially unchanged, moving from about 8.52% to about 8.52%.
The Revenue Growth assumption has fallen significantly, from about 1.69% to about 1.05%.
The Profit Margin assumption has risen meaningfully, from about 8.41% to about 13.56%.
The Future P/E has fallen significantly, from about 36.1x to about 23.3x.
Narratives on Simply Wall St let you connect Teva Pharmaceutical Industries’ story to the numbers by linking your view of the business to a financial forecast and a fair value. On the Community page, millions of investors use Narratives as an accessible way to track how changes in revenue, earnings, and margins feed into fair value, compare that to the current share price, and keep things up to date when new news or earnings arrive.
Head over to the Simply Wall St Community and follow the Narrative on Teva Pharmaceutical Industries to stay on top of:
How the affordable medicines theme and Teva’s diversified portfolio relate to expectations for margin growth and profitability through 2030.
Whether cost savings, free cash flow, and debt reduction continue to shape views on Teva’s earnings and balance sheet profile.
How reliance on key branded drugs, regulatory and competitive risks, and pipeline execution might change the gap between fair value and the current share price.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
